[A22-26] Sofosbuvir/velpatasvir (chronic hepatitis C in children 3 to < 6 years of age) - Benefit assessment according to §35a Social Code Book V
Last updated 16.05.2022
Project no.:
A22-26
Commission:
Commission awarded on 08.02.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Children from 3 to < 6 years of age with chronic HCV infection
Genotype 1, 4, 5 or 6: added benefit not proven.
Genotype 2 or 3: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-86 | Sofosbuvir/velpatasvir (chronic hepatitis C in children and adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-48 | Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V | Commission completed |